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Many UK GP practices now employ a practice pharmacist 
but little is known about how GPs and pharmacists work 





To explore GP and pharmacist perspectives on 
collaborative working within the context of optimising 
medications for patients with multimorbidity. 
 
Design and setting 
 
Semi-structured interviews with GPs and pharmacists 





Thirteen GPs and ten pharmacists were purposefully 
sampled from practices enrolled in the 3D trial. 
Participants’ views on collaborative working were explored 
with interviews that were audio-recorded, transcribed and 
analysed thematically. Saturation of data was achieved 




GPs from surgeries that employed a pharmacist tended to 
value their expertise more than GPs who had not worked 
with one.  Three key themes were identified: resources 
and competing priorities; responsibility; and professional 
boundaries. GPs valued recommendations made by 
pharmacists that were perceived to improve patient safety, 
as opposed to those that were technical and unlikely to 
benefit the patient.  Pharmacists who were not known to 
GPs felt under-valued and wanted feedback from the GPs 





A good working relationship between the GP and 
pharmacist, where each profession understood the other’s 
skills and expertise, was key. The importance of face-to-
face meetings and feedback should be considered in 
future studies of interdisciplinary interventions; and by GP 
















How this fits in (Summarise, in no more than four short sentences, what was 
previously known or believed on the topic and what your research adds, particularly 
focusing on the relevance to clinicians.) 
 
Pharmacists working within GP practices have the potential to reduce GP workload 
and to improve the quality and safety of prescribing. Optimising medications for 
complex patients with multimorbidity is one area where pharmacist expertise could 
be usefully deployed but research into how to do this effectively is lacking.  This 
study found that traditional ideas about the different professional roles of GP and 
pharmacist (e.g. concerns from some GPs that pharmacists stuck too rigidly to 
guidelines) may stop pharmacists fulfilling their potential within primary care.  Where 
GPs worked collaboratively with pharmacists (e.g. in practices that employed a 
pharmacist) they reported confidence in their professional skills and more effective 














Polypharmacy is increasing1 and the greater the number of long-term conditions a 
patient has, the greater the number of medicines they are prescribed.2  One driver of 
polypharmacy is the current disease-centred approach to health care, where patients 
with multimorbidity are prescribed different medications for each of their conditions.3  
Some criteria-based tools (e.g. STOPP/Start)4 highlight medicines that are 
potentially harmful and could be tapered down or stopped but these compete with 
disease-specific guidelines that almost always only recommend starting and 
intensifying treatment.5  Deprescribing (tapering down and stopping medications) for 
patients with multimorbidity is complex, requiring careful clinical consideration to 
balance issues such as potential loss of clinical benefit, against potential reductions 
in medication errors, adverse reactions and prescribing burden.   
 
In response to increased primary care workload pressures in the UK,6 there has 
been an increase in the number of practice pharmacists working as part of the 
primary care team.6 7  Practice pharmacists commonly have non-dispensing roles, 
including dealing with prescription requests from patients and community 
pharmacists, reviewing patients’ medications and reconciling medications following 
discharge from hospital, as well as consulting with and treating patients.  
Pharmacists could play a key role in tackling the workload associated with managing 
polypharmacy.  However, research into how best to integrate their skills is lacking. 
 
We have previously explored GP and pharmacist perspectives on the usual practice 
of medication reviews and found that being efficient (getting it done) tended to take 
priority over being thorough (doing it well).8 The aim of the current study was to 
explore GP and pharmacist views towards inter-professional working within the 




Setting, design and participants 
The present study was nested within the 3D Study, a multi-centre cluster-
randomised controlled trial of a complex intervention for people with multimorbidity.9  
The 3D intervention comprised six-monthly comprehensive reviews with a focus on 
patient-centred care, and included a pharmacist reviewing the patients’ electronic 
medical records and making up to four medication recommendations for 
consideration during a face-to-face review between the GP and patient. 
 
Semi-structured interviews were conducted GPs and pharmacists participating in the 
3D study.  Purposeful sampling from usual care and intervention practices, and 
practices with and without a practice pharmacist, allowed for a range of views and 
experiences to be captured.  Before the study, six of the pharmacists were working 
as practice pharmacists, three were Clinical Commissioning Group pharmacists (who 
tended to work across several GP practices), and one was a community pharmacist; 
and three GPs worked in practices that employed a practice pharmacist. We stopped 
recruiting interviewees once data saturation had been reached.   
 
Research team and data collection 
PD interviewed participants face to face in GP surgeries or over the phone between 
January and October 2017.   The interviews lasted between 40-60 minutes and were 
recorded using an encrypted audio-recorder. 
 
Topic guides tailored for GPs and pharmacists were developed by GPs PD and BG 
(See Boxes 1 and 2).  The first half of the interview focused on the usual practice of 
medication reviews and the second half on the 3D Study intervention.  To ground the 
interviews, GPs and pharmacists were asked to review the records of several 3D 
study patients (case studies) selected by the interviewer during the interview.  The 
GPs were asked to reflect on the pharmacist recommendations (e.g. did they look at 
them, were they useful, did they act on them, did they have any concerns) and the 
pharmacists on whether the GP had acted on their recommendations.  As topics 
emerged, more explicit questions about the pros and cons of a practice pharmacist 
were added to the topic guide.    
 
Analysis 
To aid interpretation of the meaning behind participant responses, field notes taken 
immediately after the interviews. The audio-recordings were transcribed and 
anonymised.  Field notes and interviews were imported into Nvivo version 11 and the 
interviews analysed thematically.10 PD read and coded all the transcripts.  MJR (GP), 
CC (qualitative researcher) and DM (primary care researcher) read and coded a 
subset of transcripts independently.  Emerging themes were discussed and a coding 
structure was developed over several team meetings.  The remaining interviews 
were coded using the agreed framework.  As data analysis continued, PD and CC 





The 3D study was approved by South-West (Frenchay) NHS Research Ethics 





Thirteen GPs and 10 pharmacists were interviewed.  The participant characteristics 
are shown in Table 1.  The barriers and enablers to collaborative working between 
GPs and pharmacists are described within the main themes of: resources and 
competing priorities; responsibility; and professional boundaries.  A summary of the 
findings is shown in Figure 1.   
 
Resources and competing priorities 
GPs weighed up the time and cost of employing a practice pharmacist against the 
benefit of the pharmacist taking on some of their workload. Of the six practice 
pharmacists, only one was routinely involved in medication reviews due to competing 
priorities, such as managing prescription requests, which were perceived to impact 
more on GP workload and were prioritised by the GP practices. 
 
Workload and value-for-money 
Many GPs and pharmacists talked about the current GP recruitment crisis in the UK 
and the need for practices to employ allied health professionals, such as 
pharmacists, to reduce GP workload.   
 
“We’ve had trouble recruiting GPs…a pharmacist was a good person that 
could actually do quite a lot of things that we [GPs] do at the moment.” (GP6, 
female GP) 
 
For practices that employed a pharmacist, both professions argued that they 
significantly reduced GP workload.  Several of the pharmacists and GPs argued that 
some pharmacist-led projects, particularly those focused on cost-saving, increased 
GP workload, however.   
“They’ll send it to me…it’s just the GPs’ workload, they can’t get through 
everything.” (P2, female practice pharmacist) 
 
“Tamsulosin capsules instead of Tamsulosin tablets to save like £3.50 a 
month …it’s kind of frustrating that we have to waste your [the GP’s] time and 
I can’t come to you with a real issue” (P4, female non-practice pharmacist) 
 
There were mixed views about whether a practice-employed pharmacist was good 
value-for-money.  Several pharmacists commented that they were cheaper to 
employ than a GP.  Some GPs argued, however, that pharmacists tended to take 
longer to complete tasks than GPs and so, although pharmacists cost less per hour 
to employ than GPs, they were not necessarily more cost effective. GPs commented 
that, owing to pharmacists spending longer on tasks, the quality of their work was 
high.  Other GPs commented that pharmacists were more expensive than other 
professionals, such as nurses. 
 
 
“So pharmacists are good at that kind of thing and they’re cheaper than GPs, 
it makes a lot of sense” (P3, male practice pharmacist) 
 
“I think that she [the pharmacist] would probably take twice or three times as 
long doing it as a GP would but I’ve got no doubt that she would do it a hundred 
percent correct… in some ways GPs are the most quick person at dealing with 
almost anything (laughs)…” (GP4, male GP)  
 
 “The downside of it is that they’re a more expensive member of staff than a 
nurse.  I think we’ve gained a lot of benefit from getting the nurses a bit more 
specialised…you get more for your money.” (GP10, male GP) 
 
Competing priorities 
Medication reviews were not prioritised by practices for many of the practice 
pharmacists.  Some GPs reasoned that pharmacist-led medication reviews would 
not impact much on GP workload as medication reviews were being done as part of 
routine consultations.  Their skills were viewed by practices as being better utilized 
carrying out other duties, such as dealing with prescription enquires.   
“They might take away some [workload] but it would probably be quite small 
because we’re all doing this as part of our general consultation so we’re not 
always doing it sort of as a separate issue.” (GP2, female GP) 
 
“We have a big workload in terms of repeat prescriptions so some help with 
getting through that…patients who ring up with medication queries he can 
quite often deal with the queries…He can fend off a lot of those.” (GP9, male 
GP) 
 
One pharmacist appeared frustrated that GP practices focused too much on 
reducing GP workload and this led to pharmacists carrying out more mundane tasks: 
 “Some of the pharmacists are just doing all the medicines management 
which we’re not supposed to be doing and I think if you asked those practices 
they’d say that’s the pro of having a pharmacist there that someone’s just sat 
signing prescriptions all day” (P9, male practice pharmacist) 
 
Responsibility 
For most interviewees, the responsibility for prescribing decisions lay with the GP.  
However, some pharmacists were independent prescribers and would make 
changes to patient’s medications without involving the GP.  Many GPs were reluctant 
to relinquish control of prescribing decisions and preferred having decisions 
approved by them.  Other GPs felt overwhelmed by the responsibility of prescribing 
increasingly complex medications and valued advice and expertise from the 
pharmacists and practice nurses.  
 
 
Several GPs, particularly those who had a good knowledge of and relationship with 
their patients, preferred to remain in control of prescribing decisions and some 
pharmacists liked to seek the reassurance of GPs.  There was a tension between 
GPs staying in control of decisions and reducing their workload by delegating 
responsibility/tasks to pharmacists.   
“we [GPs] are quite possessive of our patients…some of us who have been 
here a long time and know our patients very well need to let go 
so…personally I would probably be happy for the pharmacist to work it out 
and I don’t know that I would need to ok it.” (GP1, Female GP) 
 
“practice notes to the GPs to just say this is what I’m doing, are you happy 
with that?... for me it’s quite a nice little buffer…I can just run past things in 
front of the GPs” (P6, female practice pharmacist) 
 
Many GPs felt overwhelmed by the responsibility of prescribing and some GPs 
described an increasing expectation for GPs to prescribe complex medications that 
would have previously been prescribed only by hospital doctors.  Many of the GPs 
welcomed the pharmacist’s advice and expertise but preferred to remain in control of 
decisions. 
“There’s been just the most amazing difference between prescribing when I first 
started being a GP and prescribing now…and now almost nobody is seen again 
at the hospital…it is a massive responsibility which I really don’t think that we 
are, um, able to do safely without help from other professionals” (GP1, Female 
GP) 
 
“She [the pharmacist] will perhaps point out anti-cholinergic burden in elderly 
patients or dementia patients…we can then discuss- GP makes a decision 
and then she will take the required action.  Yeah.  So that’s incredibly 
valuable.” (GP5, female GP) 
 
Pharmacists who were independent prescribers deferred prescribing decisions to the 
GPs when they encountered conditions that were outside of their area of expertise.   
“I’m a prescriber by the way…I’m basically working independently all the time 
..I don’t ask for any kind of guidance on any of that…diabetic neuropathy and 
erectile dysfunction, those are a couple of areas where I don’t initiate 
treatment myself just ‘cos I kind of haven’t, um, really worked that through…I 









GPs had mixed views about whether pharmacists should have the authority to 
suggest and make changes to patients’ medications, with some GPs valuing 
pharmacist’s expertise and knowledge of medicines. Other GPs raised concerns that 
pharmacists lacked the key attributes required to make clinical decisions, including a 
trusting relationship with the patient and knowledge of their medical and social 
background.  Within the context of the 3D trial, GPs most valued pharmacist 
recommendations that improved the safety of prescribing and least valued 
recommendations which they perceived as being technical and unlikely to lead to 
patient benefit. 
 
Clinical decision-making skills of pharmacists 
Several GPs expressed dismay about pharmacist recommendations that they 
deemed as “treating the numbers” (GP1) rather than the patient, such as 
recommendations to change a patient’s statin in line with the most recent NICE 
guidance.  GPs tended to ignore this advice because they felt that in the context of 
often complex social and medical problems, altering a statin was unlikely to make a 
significant difference to the patient’s health.  In general, the GPs perceived that the 
pharmacists tended to be driven by following guidelines to the letter.   
 
“I kind of didn’t really feel greatly engaged with changing that [the statin] 
particularly ‘cos, you know, if your cholesterol’s 3.4 I don’t think there’s a lot to 
be gained really.” (GP6, female GP) 
 
Some GPs thought that very few pharmacist recommendations were made.  One 
such GP was surprised to find that pharmacist recommendations had been made for 
all the case study patients.  
“there was never any pharmacy information available so the pharmacist 
hadn’t done it…it’s my recollection that I was doing these reviews and the 
pharmacist hadn’t provided any information… whether that was just luck 
because all of them [the case study patients] had, hadn’t they, and in fact 
we’d acted on a few of them” (GP8, male GP) 
 
Several GPs questioned the clinical decision-making skills of pharmacists, 
commenting that they were good at applying clinical guidelines but struggled to think 
outside the box.  A small number of GPs described the pharmacist as being 
technical and clerical rather than clinical.   
“They [pharmacists] want strict protocols- their job is very technical, they have 
to get the end dosage right, quantities etc.  Sometimes, I mean clinical 
medicine isn’t- you’ve got to think outside the box…” (GP3, male GP)  
 
“They [pharmacists] are perhaps less willing to tolerate the uncertainty that a 




In contrast, many of the GPs valued pharmacist’s knowledge of medicines and, 
feeling de-skilled in chronic disease management (a point also noted by 
pharmacists), welcomed the pharmacist’s input.  GPs particularly valued pharmacist 
recommendations which improved the safety of prescribing e.g. picking up 
medication errors and adjusting medication doses due to renal impairment.  
“they [pharmacists] have such a good clinical knowledge and they also have 
that kind of pharmacological knowledge …I just think as a GP you can’t 
possibly know all of those things. (GP12, female GP) 
 
“A patient…on a vitamin D replacement, on a high dose sort of quick 
replacement that had never been dropped down…a good reflection of not 




Hierarchy of authority 
Some GPs described a hierarchy of authority, whereby the opinion of hospital 
doctors and GPs took precedence over that of the pharmacist.  In contrast, other 
GPs and pharmacists argued that pharmacists had a better eye for detail and would 
pick up and challenge medication errors made by doctors. 
“They’re [hospital doctors] the gods (laughs) in hospitals as far as a lot of the 
elder patients are concerned so they’re [the patients] not going to want to go 
against them unless we have got a really good reason for stopping and we have 
sent them [the patients] for that opinion” (GP2, female GP) 
 
 “I will spot things that the GPs probably won’t and looking - I don’t take what 




Relationship between the GP and pharmacist 
Pharmacists that were not attached to a specific practice described some difficult 
relationships with GPs, where they felt poorly understood and under-utilized.  One 
non-practice pharmacist wanted feedback from GPs to understand the reasons that 
her recommendations had not been implemented. 
“there were other surgeries that didn’t have that open-mindedness and didn’t- 
I suppose were sort of old-fashioned really in the sense that they didn’t want 
anybody else to sort of interfere with the medication” (P8, male non-practice  
pharmacist) 
 
“I sometimes feel that we don’t get utilized…people [need to] realize that 
pharmacists are more useful than just sticking labels on boxes …The patients 
 
 
don’t realise, the GPs don’t realise…I would check back to see how they got 
on.  Yeah, rarely the GP, erm, took upon my suggestion…I wasn’t being 
nosey, I was just interested to see, did they take heed or did they not” (P4, 
female non-practice pharmacist) 
 
In contrast, the practice pharmacists felt valued as part of the practice team, and 
many GPs and pharmacists described a good collaborative relationship with the two 
professions seeking advice from one another.  One pharmacist (P6) had joined a 
practice since taking part in the 3D Study and commented on the value of getting to 
know GPs in the practice through informal face to face chats. 
 
“I feel we couldn’t manage without her [the pharmacist] at all.  She a vital 
member of the clinical team.” (GP5, female GP) 
 
“it’s lovely working as part of the team because they’re [the GPs] throwing 
questions at me…they know what I can do and I know what they can…it [the 
3D Study] was good but it felt slightly different because you didn’t know 
everybody, you didn’t know quite how to word things…you can actually have a 
face to face chat about it…it’s the fact that you’re there all the time for them to 





This study identified barriers and enablers to collaborative working between GPs and 
pharmacists within the context of optimising medications for patients with 
multimorbidity.  A good working relationship was key to effective integrated working 
and GPs who worked in practices that employed a pharmacist were more likely to 
value their professional expertise.  In some practices, independent prescribing 
pharmacists prescribed within clearly defined competencies deferring decisions 
outside of this to GPs.  This suited both the pharmacist, who liked the safety net of 
“running things past” the GP, and the GP, who preferred to remain in control of 
complex prescribing decisions but benefited from the pharmacist’s knowledge.  Most 
interviewees felt that pharmacists could reduce GP workload by taking on routine 
prescribing tasks, although not all pharmacists thought this the best of use of their 
time. In contrast, it wasn’t clear that pharmacists doing medication reviews would 
reduce GP workload even if valuable in other ways.  Within the context of the 3D 
Study, GPs valued pharmacist recommendations that improved the safety of 
prescribing but tended to ignore recommendations which they deemed as being 
technical and of little benefit to the patient.  GPs who worked in practices that did not 
employ a practice-pharmacist were more likely to question pharmacists’ clinical 
decision-making skills and ability to ‘think outside the box’.     
 
Strengths and limitations 
A key strength is that the interviews were grounded using real patient case studies, 
which encouraged GPs and pharmacists to reflect on real decisions and yielded 
richer information than talking in generalities.  One GP, for example, commented that 
few recommendations were made by the pharmacist.  By reviewing the case study 
patients, this view could be challenged, as it was evident that the pharmacist had 
made recommendations and that GPs within the practice had acted on some of 
them.  A further strength is the iterative approach with analysis of earlier interviews 
informing the focus of later interviews.  A range of views was captured, including 
those of community, clinical and practice pharmacists, and GPs working in practices 
with and without a practice pharmacist.  One limitation is that all interviewees were 
recruited from practices enrolled in the 3D study, introducing potential bias towards 
better performing GP practices.  A further limitation is that the interviews were 
conducted by a GP.  This may have influenced how forthcoming the interviewees 
were, particularly in terms of being negative about one another’s profession.   
 
Comparisons with existing literature   
Most interviewees in the present study argued that pharmacists had a role to play in 
reducing GP workload, particularly in performing tasks such as responding to 
prescription requests and reconciling medications after hospital discharge.  Several 
GPs commented that pharmacist-led medication reviews were unlikely to impact 
significantly on GP workload, however, since these were being done in a time-
efficient manner and pharmacists tended to require more time to complete a review.   
These views were shared by GPs in New Zealand, some of whom argued that 
pharmacist-led medication reviews increased GP workload since the GPs were 
 
 
required to action pharmacist advice.11  Other barriers to collaborative working 
reported in the literature include funding,12  concerns from GPs that community 
pharmacists may be commercially driven,13 pharmacist fears about stepping on GPs 
toes, 10 and GPs being too busy to speak to pharmacists.14   
 
There is evidence from this study and others from similar contexts internationally that 
GPs value pharmacists’ expertise and the safety net they provided by checking for 
medication errors.8,12  GPs in the present study least valued pharmacist 
recommendations which they perceived as being ‘technical’ rather than having clear 
value for patients, particularly those with complex medical and social backgrounds.  
GPs in other studies were similarly frustrated by recommendations that were 
perceived as applying science and theory without considering the individual patient.15  
Some pharmacists in the present study, particularly those who were not known to the 
GPs, would have valued feedback from the GPs about the acceptability of their 
recommendations, a view shared by pharmacists in New Zealand.16  
 
In this study and others, GPs views towards pharmacists were on a spectrum – at one 
end pharmacists were viewed as professional equals and experts in medicines, and 
at the other end as lacking clinical decision-making skills and being subordinate to 
GPs within the medical hierarchy.11 17 18 A study of patients’ found they believed that 
reviewing medications was the doctor’s rather than the pharmacist’s role, and that they 
trusted their doctor most.17  This view reflects the traditional idea of medical 
dominance, under which doctors are in charge not only of their patients but also of 
allied health professionals contributing to care.18   
 
Responsibility for prescribing decisions in this and other similar studies lay mostly with 
GPs, many of whom did not want to relinquish control.13,14,18   However, several GPs 
in the present study felt overwhelmed by the responsibility of prescribing complex 
medications, and were grateful for pharmacist input.   The ability to independently 
prescribe medication is seen as an important part of clinical autonomy, which was 
previously the preserve of doctors, and allowing allied health professionals to 
prescribe independently can be perceived as a threat to medical dominance.19 20  In 
the present study, interviewees described a middle ground where some pharmacists 
were able to prescribe independently within their area of expertise but would defer 
decisions outside their expertise to the GP.  This appeared to suit both the GP, who 
liked to remain in control of decisions, and the pharmacist, who valued the safety net 
of running things past the GP. 
 
 
Implications for research and practice 
In this study, ‘knowing’ each other was an important underpinning for effective 
collaborative working between GPs and pharmacists, where each profession values, 
learns from and utilises the other’s expertise.  In practices where GPs and 
pharmacists had little personal contact or knowledge of each other, pharmacists 
 
 
described feeling under-valued and under-utilized and GPs expressed concerns that 
pharmacists tended to stick rigidly to guidelines and were unable to ‘think outside the 
box’.   
 
A key finding of this study was the importance of contact between the pharmacist, 
patient and GP.  Within the 3D Study model, many of the GPs argued that 
pharmacists were unable to make meaningful recommendations because they 
lacked familiarity with the patient, their medical background and social context.  
Pharmacists who were not known to the GPs reported that feedback from the GPs 
about their recommendations, particularly those that the GP chose not to action, 
would have been helpful.  Developing a trusting relationship between the pharmacist, 
patient and GP through face-to-face meetings should be at the centre of future 
service developments and trial interventions. 
 
In this study, only one of the practice pharmacists was routinely involved in 
medicines optimisation and medication reviews.  Other roles, such as managing 
repeat (refill) and acute (one-off) prescription requests that did not involve a 
consultation, and reconciling medications after hospital discharge, were perceived by 
interviewees as having more impact on GP workload and so were prioritised by 
practices.  Further research is needed to establish the roles and responsibilities of 
practice pharmacists currently working in GP practices including to what extent they 
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Box 1: GP interview topic guide  
 
Usual practice  
 
• Before we get into the specifics, I’m interested in understanding how repeat 
medications are reviewed in your practice?’ [how often, within/outside of 
consultations, patient involvement, purpose, barriers/facilitators] 
• Can you tell me about your experience of reviewing medications for patients with 
polypharmacy ? [different to other medication reviews?] 
• Do pharmacists play a role in medication reviews in your practice?  [CCG 
pharmacist or practice pharmacist] 
• Are any other non-GP staff involved in medication reviews in your practice? 
 
 
Usual practice case patients 
• Can you think of any non-3D patients who are prescribed lots of medications who 
you could look up on Emis? 




• I’d like to ask you to focus more on the 3D Study now.  How have you found 
reviewing patient’s medications during the 3D consultations? [purpose of the 




3D Study case patients (2-3 for each interview) 
• Can you have a read over the record for this patient and talk me through how you 
might have come to the decisions about their medications? [changes made; 
pharmacist recommendations – looked at, useful, acted on, concerns; patient 
involvement; typical of other reviews; same/different to usual practice] 
 
Any other issues 





Box 2: Pharmacist interview topic guide 
 
Usual practice  
 
• Before we get into the specifics, I want to find out a bit more about your role as a 
pharmacist outside of the 3D study.  In particular, whether you are involved in 
medication reviews for patients?  [driven by cost or CCG targets or led by the 
practice?, face to face or computer led? Useful or not? Barriers, facilitators]  
• Can you tell me about the last time you were involved in medication reviews for a 
practice? [typical?]  
• How have you found working with practices?  
• Have you been involved in medication reviews for patients with polypharmacy? 
[driven by cost or CCG targets or led by the practice?, face to face or computer 




3D Study case patients (2-3 for each interview) 
• Before we go on to talk about the case study patients, can you tell me any 
thoughts you have about the medication reviews for the 3D study? (working with 
practices, doing the reviews, purpose, useful) 
• Can you have a read over the record for this patient and talk me through the 
process you might have gone through when you reviewed this patient’s 
medications? 
• Recommendations (types of meds stopped/started, purpose of stopping/starting 
them e.g. safety, pill burden, guidelines) 
• Typical of other 3D reviews? 
• Same/different to usual practice 
• Reflect on whether the GP acted on the recommendations (typical?) 
 
 
Any other issues 




Table 1: Participant Characteristics 




 Male 3 
 Female 7 
Estimated age in years  
 31-40 6 
 41-50 4 
Job role  
 Community pharmacist 1 
 CCG pharmacist 3 
 Practice pharmacist 6 
Years qualified as a pharmacist  
 5-9 4 
 10-14 3 
 > 15 3 
Years working in primary care (for the six practice pharmacists only) 






Intervention or usual care practice  
 Delivered the 3D intervention 8 
 Working in usual care practice 2 
 




 Male 5 
 Female 8 
Estimated age  
 30-39 6 
 40-49 2 
 50-59 5 
Years qualified as a GP  
 < 5 3 
 5-9 4 
 10-14 3 
 > 15 3 
Job role  




Intervention or usual care practice   
 Intervention practice 9 




Figure1. GP and pharmacist reported barriers and enablers of collaborative 
working 
 
 
 
 
 
